Literature DB >> 30679227

Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note.

Michal Zawadzki1, Jerzy Walecki1, Boguslaw Kostkiewicz2, Kacper Kostyra2, Monica Smith Pearl3,4, Meiyappan Solaiyappan3, Piotr Walczak3, Miroslaw Janowski3.   

Abstract

Patients with malignant brain tumors have a poor prognosis. The blood-brain barrier (BBB) is considered a primary obstacle in therapeutic drug delivery to the brain. Intra-arterial (IA) delivery of therapeutic agents following osmotic BBB opening has been attempted for years, but high variability has limited its widespread implementation. It has recently been shown in animal studies that MRI is superior to X-ray for guiding IA infusions, as it allows direct visualization of the brain parenchyma supplied by the catheter and facilitates predictable drug targeting. Moreover, PET imaging has shown that IA rather than intravenous delivery of bevacizumab results in accumulation in the brain, providing a strong rationale for using the IA route. We present a patient with recurrent butterfly glioblastoma enrolled in a first-in-man MRI-guided neurointervention for targeted IA drug delivery. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  brain; intervention; malignant; mri; technique

Mesh:

Substances:

Year:  2019        PMID: 30679227      PMCID: PMC6347944          DOI: 10.1136/bcr-2018-014469

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery.

Authors:  E A Neuwelt; E P Frenkel; J T Diehl; K R Maravilla; L H Vu; W K Clark; S I Rapoport; P A Barnett; S A Hill; S E Lewis; A L Ehle; C W Beyer; R J Moore
Journal:  Trans Am Neurol Assoc       Date:  1979

2.  Predicting and optimizing the territory of blood-brain barrier opening by superselective intra-arterial cerebral infusion under dynamic susceptibility contrast MRI guidance.

Authors:  Miroslaw Janowski; Piotr Walczak; Monica S Pearl
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-05       Impact factor: 6.200

3.  A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier.

Authors:  Wojciech G Lesniak; Chengyan Chu; Anna Jablonska; Yong Du; Martin G Pomper; Piotr Walczak; Miroslaw Janowski
Journal:  J Nucl Med       Date:  2018-10-12       Impact factor: 10.057

4.  Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.

Authors:  Shamik Chakraborty; Christopher G Filippi; Jan-Karl Burkhardt; Sherese Fralin; Ashley Ray; Tamika Wong; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Exp Ther Oncol       Date:  2016-11

5.  Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.

Authors:  Rachel A Alter; Timothy G White; Andrew A Fanous; Shamik Chakraborty; Christopher G Filippi; David J Pisapia; Apostolos John Tsiouris; John A Boockvar
Journal:  J Exp Ther Oncol       Date:  2017-05

6.  Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.

Authors:  John A Boockvar; Apostolos J Tsiouris; Christoph P Hofstetter; Ilhami Kovanlikaya; Sherese Fralin; Kartik Kesavabhotla; Stephen M Seedial; Susan C Pannullo; Theodore H Schwartz; Philip Stieg; Robert D Zimmerman; Jared Knopman; Ronald J Scheff; Paul Christos; Shankar Vallabhajosula; Howard A Riina
Journal:  J Neurosurg       Date:  2010-10-22       Impact factor: 5.115

  6 in total
  7 in total

1.  PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration.

Authors:  Wojciech G Lesniak; Chengyan Chu; Anna Jablonska; Babak Behnam Azad; Olivier Zwaenepoel; Michal Zawadzki; Ala Lisok; Martin G Pomper; Piotr Walczak; Jan Gettemans; Miroslaw Janowski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-03       Impact factor: 9.236

Review 2.  Hyperosmolar blood-brain barrier opening using intra-arterial injection of hyperosmotic mannitol in mice under real-time MRI guidance.

Authors:  Chengyan Chu; Anna Jablonska; Yue Gao; Xiaoyan Lan; Wojciech G Lesniak; Yajie Liang; Guanshu Liu; Shen Li; Tim Magnus; Monica Pearl; Miroslaw Janowski; Piotr Walczak
Journal:  Nat Protoc       Date:  2021-12-13       Impact factor: 13.491

3.  Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointervention.

Authors:  Lin Chen; Jing Liu; Chengyan Chu; Zheng Han; Nirhbay Yadav; Jiadi Xu; Renyuan Bai; Verena Staedtke; Monica Pearl; Piotr Walczak; Peter van Zijl; Miroslaw Janowski; Guanshu Liu
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

4.  Modeling hyperosmotic blood-brain barrier opening within human tissue-engineered in vitro brain microvessels.

Authors:  Raleigh M Linville; Jackson G DeStefano; Matt B Sklar; Chengyan Chu; Piotr Walczak; Peter C Searson
Journal:  J Cereb Blood Flow Metab       Date:  2019-08-08       Impact factor: 6.960

5.  Reversible blood-brain barrier opening utilizing the membrane active peptide melittin in vitro and in vivo.

Authors:  Raleigh M Linville; Alexander Komin; Xiaoyan Lan; Jackson G DeStefano; Chengyan Chu; Guanshu Liu; Piotr Walczak; Kalina Hristova; Peter C Searson
Journal:  Biomaterials       Date:  2021-06-10       Impact factor: 15.304

Review 6.  Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles.

Authors:  Sylwia Dabrowska; Anna Andrzejewska; Barbara Lukomska; Miroslaw Janowski
Journal:  J Neuroinflammation       Date:  2019-09-12       Impact factor: 8.322

7.  A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.

Authors:  Mateusz Pinkiewicz; Milosz Pinkiewicz; Jerzy Walecki; Michał Zawadzki
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.